Reported about 24 hours ago
Novartis (NVS), the prominent European pharmaceutical company, recently revealed plans to invest $23 billion in U.S.-based manufacturing aimed at enhancing research and development for its key drugs. This strategic initiative aligns with evolving supply chain dynamics and could mitigate potential tariff impacts on pharmaceutical imports. As Novartis aims to produce all major medicines in the U.S., the investment reflects a proactive approach to maintain competitiveness, especially in light of potential market challenges ahead.
Source: YAHOO